Celgene Slides After Deciding Against Revlimid Label Expansion
July 26, 2016 at 12:27 PM EDT
Revlimid didn't improve overall survival in a trial of diffuse large B-cell lymphoma patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.